Compound Profiling und Screening
The World Health Organization (WHO) considers the spread of microorganisms which are resistant to the most common antibiotics an increasing threat to the well-being of the world population. Not only is the number of patients increasing whose infectious disease can no longer be treated, but also in some circumstances patients with other severe diseases will not be treated if the therapy is accompanied with suppression of the immune system and thus, an increased risk of infection. Thus, new active agents for the treatment of infectious diseases are urgently needed, as well as the responsible use of existing antibiotics. Prerequisites for the discovery of new drugs are relevant biological screening assays together with compound libraries of broad chemical diversity. We perform primary screens, based either on own protocols or on protocols developed by cooperation partners and transferred to our infrastructure. In cooperation with partners we also perform secondary assays to optimize first primary hits.
There are no results
- Novel targets for short-course tuberculosis therapy: MYCOBACTERIUM TUBERCULOSIS
- New tools for the diagnosis of Candida albicans: LAB – IN – A – HANKIE
- A systems biology approach for the treatment of nosocomial infections with Candida albicans: From an commensal organism to a life-threatening pathogen: DR. JEKYLL AND MR. HYDE
- Analysis of the mechanisms of action of anti-infectives : ANTI-INFEKTIVA
- Search and development of new antimycotics: CANDIDA ALBICANS
- Screening for Inhibitors of the NS2_3 Protease of the Hepatitis C Virus
- Virulence factor alpha-Hemolysin from Staphylococcus aureus
- Sensitizing Escherichia coli for Erythromycin
Bachelor & Master
Are you interested in a bachelor or master thesis? We are looking forward to your request!